Trevi Therapeutics (TRVI) Amortization of Deferred Charges (2018 - 2023)

Trevi Therapeutics' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $105000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 6.25% year-over-year to $105000.0; the TTM figure through Mar 2026 stood at $430000.0 (down 4.87% YoY), while the FY2025 annual figure was $437000.0, down 5.0% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $105000.0, down from $107000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $420000.0 in Q4 2022, with the low at -$87000.0 in Q2 2022.
• The 5-year median for Amortization of Deferred Charges is $108000.0 (2025), against an average of $111705.9.
• The sharpest annual moves came in 2022 and 2025: Amortization of Deferred Charges slumped 159.59% in 2022, then soared 272.41% in 2025.
• Trevi Therapeutics' Amortization of Deferred Charges stood at $420000.0 in 2022, then sank by 71.9% to $118000.0 in 2023, then surged by 67.8% to $198000.0 in 2024, then tumbled by 45.96% to $107000.0 in 2025, then slipped by 1.87% to $105000.0 in 2026.
• Business Quant data shows TRVI's Amortization of Deferred Charges at $105000.0 in Q1 2026, $107000.0 in Q4 2025, and $108000.0 in Q3 2025.